Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Oct;25(5):e461-e474.
doi: 10.3747/co.25.4092. Epub 2018 Oct 31.

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia

C Owen  1 , A S Gerrie  2 , V Banerji  3 , S Assouline  4 , C Chen  5 , K S Robinson  6 , E Lye  7 , G Fraser  8
Affiliations
Practice Guideline

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia

C Owen et al. Curr Oncol. 2018 Oct.

Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of cll; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of cll. Consensus recommendations based on available evidence are presented for the first-line treatment of cll.

Keywords: Key Words Chronic lymphocytic leukemia; cll; fitness; prognosis; treatment.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: CO reports personal fees from Roche, Janssen, Gilead, AbbVie, Merck, AstraZeneca, and Lundbeck/Teva outside the submitted work; VB sits on advisory boards for AstraZeneca, AbbVie, Janssen, Lundbeck, Gilead, Roche, and has received grants from Research Manitoba, the CancerCare Manitoba Foundation, and Lundbeck outside the submitted work; ASG reports personal fees from Janssen, Lundbeck, and AbbVie outside the submitted work; SA reports personal fees from Roche and Pfizer outside the submitted work; CC reports other considerations from Celgene, Janssen, and Gilead outside the submitted work; KSR reports personal fees from Celgene, Janssen, Gilead, Roche, AstraZeneca, and AbbVie outside the submitted work; EL reports grants from Roche, Gilead, and Lundbeck during the conduct of the study; GF reports grants and personal fees from Celgene and AbbVie, and personal fees from Janssen outside the submitted work.

References

    1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052–7. doi: 10.1056/NEJM199510193331606. - DOI - PubMed
    1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
    1. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci), Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL) [Web page] Bethesda, MD: NCI; n.d. [Available at: http://seer.cancer.gov/statfacts/html/clyl.html; cited 20 September 2017]
    1. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–60. doi: 10.1002/ajh.23979. - DOI - PubMed
    1. Statistics Canada. Number and rates of new cases of primary cancer (based on the November 2017 CCR tabulation file), by cancer type, age group and sex [Web resource] Ottawa ON: Government of Canada; 2017. Table 13-10-0111-01. [Available at: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011101; cited 25 March 2018]

Publication types

LinkOut - more resources